



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Se

## NOTICE OF ALLOWANCE AND FEE(S) DUE

000513      7590      02/20/2004  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K STREET N. W.  
SUITE 800  
WASHINGTON, DC 20006-1021

EXAMINER	
CHANG, CELIA C	
ART UNIT	PAPER NUMBER
1625	

DATE MAILED: 02/20/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/031,716	03/26/2002	Yufu Sagara	2002-0068A	6726

TITLE OF INVENTION: NOVEL AMIDE DERIVATIVES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	05/20/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

### HOW TO REPLY TO THIS NOTICE:

#### I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.
- B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
  - Applicant claims SMALL ENTITY status.  
See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

**IMPORTANT REMINDER:** Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** **Mail Stop ISSUE FEE**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, Virginia 22313-1450**  
**or Fax** **(703) 746-4000**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

000513 7590 02/20/2004

WENDEROTH, LIND & PONACK, L.L.P.  
 2033 K STREET N. W.  
 SUITE 800  
 WASHINGTON, DC 20006-1021

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

**Certificate of Mailing or Transmission**  
 I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

(Depositor's name)

(Signature)

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/031,716	03/26/2002	Yufu Sagara	2002-0068A	6726

### TITLE OF INVENTION: NOVEL AMIDE DERIVATIVES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	05/20/2004
EXAMINER	ART UNIT		CLASS-SUBCLASS		
CHANG, CELIA C	1625		514-331000		

### 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  
 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 \_\_\_\_\_  
 2 \_\_\_\_\_  
 3 \_\_\_\_\_

### 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent):  individual  corporation or other private group entity  government

4a. The following fee(s) are enclosed:

4b. Payment of Fee(s):

Issue Fee  
 Publication Fee  
 Advance Order - # of Copies \_\_\_\_\_

A check in the amount of the fee(s) is enclosed.  
 Payment by credit card. Form PTO-2038 is attached.  
 The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number \_\_\_\_\_ (enclose an extra copy of this form).

Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

(Authorized Signature)	(Date)	<p>NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.</p> <p>This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.</p> <p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.</p>
TRANSMIT THIS FORM WITH FEE(S)		



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/031,716	03/26/2002	Yufu Sagara	2002-0068A	6726
000513	7590	02/20/2004		EXAMINER
				CHANG, CELIA C
			ART UNIT	PAPER NUMBER
				1625

DATE MAILED: 02/20/2004

## Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/031,716	SAGARA ET AL.
	Examiner Celia Chang	Art Unit 1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS**. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to amendment Sept. 29, 2003 and ex. amendment attached.
2.  The allowed claim(s) is/are 20 and 25-38.
3.  The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All    b)  Some\*    c)  None    of the:
    1.  Certified copies of the priority documents have been received.
    2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application (PTO-152)
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

## DETAILED ACTION

1. Amendment and response filed by applicants in paper No. 11, dated Sept. 29, 2003 have been entered and considered carefully.

Claims 1-19, 21-24 have been canceled. Claims 20, 25-38 are pending.

2. *Examiner's Amendment*

**Claim 20.** (currently amended) page 4, line 1 , delete the term "m,n and s"

and in its place insert, --m and n--;

after 0, 1 or 2, insert --s is 1--.

3. *Reason for Allowance*

The following is an examiner's statement of reasons for allowance:

Applicants have amended the claims limiting to the elected and allowable subject matter. The above examiner's amendment made the process and the compound claims consistent with the scope of the allowable subject matter. Claims 20, 25-38 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


OACS/Chang  
Feb. 12, 2004

  
Celia Chang  
Primary Examiner  
Art Unit 1625


THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0925.  
AMENDMENTS TO THE CLAIMS.

Claims 1-19 (Cancelled)

Claim 20<sup>15</sup> (Currently Amended) A process for producing a compound represented by the general formula [I-1]:



in which A<sup>a</sup> stands for a group of the formula [a<sub>0</sub>]




Ar<sup>1</sup>, Ar<sup>2</sup> and Ar<sup>3</sup> each independently stands for optionally substituted phenyl, the substituent being selected from the group consisting of halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, carbamoyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl; R<sup>1</sup> stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> each independently stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl, or R<sup>2</sup> and R<sup>3</sup>, or R<sup>4</sup> and R<sup>5</sup>, may together stand for, independently of each other, optionally substituted trimethylene, propenylene, tetramethylene or 2-butenylene group, the substituent being selected from the group consisting of oxo, hydroxyl, amino, lower alkoxy, lower alkanoyloxy, lower alkylamino, di-lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower


alkylcarbamoyl, di-lower alkylcarbamoyl, imidazolyl and a group represented by  $-R^7$ ,  $R^7$  standing for optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkoxycarbonyl and imidazolyl;  $R^{60}$  stands for hydrogen,  $C_1-C_{10}$  alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl; and k, m, n, s, X and Y have later defined significations} significations

or salts thereof, which comprises reacting carboxylic acid of the general formula [II]:




[in in which  $\text{Ar}^{1\text{p}}$ ,  $\text{Ar}^{2\text{p}}$  and  $\text{Ar}^{3\text{p}}$  each independently stands for optionally substituted phenyl, the substituent being selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkoxy and di-lower alkylcarbamoyl and optionally protected hydroxyl, carbamoyl and lower alkylcarbamoyl; and  $\text{R}^{1\text{p}}$  stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of di-lower alkylcarbamoyl, optionally protected hydroxyl, amino, carbamoyl, lower alkylcarbamoyl and imidazolyl groups] groups

or salt or reactive derivative thereof with a compound of the general formula [III]:




[in which  $A^{ap}$  stands for a group of the formula  $[a_{op}]$ ]



~~s is 0~~

~~m and n~~  
k means 0 or 1; ~~m, n and s~~ each independently means 0, 1 or 2; R<sup>2p</sup>, R<sup>3p</sup>, R<sup>4p</sup> and R<sup>5p</sup> each independently stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of di-lower alkylcarbamoyl and optionally protected hydroxyl, amino, carbamoyl, lower alkylcarbamoyl and imidazolyl groups, or R<sup>2p</sup> and R<sup>3p</sup>, or R<sup>4p</sup> and R<sup>5p</sup>, together form, each independently of the other pair, optionally substituted trimethylene, propenylene, tetramethylene or 2-butenylene, the substituent being selected from the group consisting of lower alkoxy, lower alkanoyloxy, di-lower alkylamino, lower alkoxycarbonyl, di-lower alkylcarbamoyl, a group represented by -R<sup>7p</sup> and optionally protected oxo, hydroxyl, amino, lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, carbamoyl, lower alkylcarbamoyl and imidazolyl groups; R<sup>7p</sup> stands for optionally substituted lower alkyl, the substituent being selected from the group consisting of di-lower alkylcarbamoyl and lower alkoxycarbonyl, and optionally protected hydroxyl, amino, carbamoyl, lower alkylcarbamoyl and imidazolyl groups; R<sup>60p</sup> stands for imino-protecting group, C<sub>1</sub>-C<sub>10</sub> alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion being optionally substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl; X stands for carbonyl or methylene; and Y stands for nitrogen or ~~methine~~ methine

or a salt thereof to form a compound represented by the general formula [IV-1]




~~in~~ in which A<sup>ap</sup>, Ar<sup>1p</sup>, Ar<sup>2p</sup>, Ar<sup>3p</sup>, k, m, n, R<sup>1p</sup>, R<sup>2p</sup>, R<sup>3p</sup>, R<sup>4p</sup>, R<sup>5p</sup>, X and Y have the above significations


or a salt thereof, and if necessary removing the protective group(s).

Claims 21-24 (Cancelled)

Claim 25 (New) Compounds which are represented by the following general formula [I]



in which A stands for a group of the following formula [a<sub>0</sub>]




Ar<sup>1</sup>, Ar<sup>2</sup> and Ar<sup>3</sup> each independently stands for optionally substituted phenyl, the substituent being selected from the group consisting of halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, carbamoyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl; k means 0 or 1; m and n each independently means 0, 1 or 2; s means 1; R<sup>1</sup> stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl; R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> each independently stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl, or R<sup>2</sup> and R<sup>3</sup>, or R<sup>4</sup> and R<sup>5</sup>, may together stand for, independently of each other, optionally substituted trimethylene, propenylene, tetramethylene or 2-butenylene group, the substituent being selected from the group consisting of oxo, hydroxyl, amino, lower alkoxy, lower alkanoyloxy, lower alkylamino, di-lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, imidazolyl and a group represented by -R<sup>7</sup>, R<sup>7</sup> standing for optionally


substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkoxy carbonyl and imidazolyl; R<sup>60</sup> stands for hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl; X stands for carbonyl or methylene; and Y stands for nitrogen or methane or salts thereof.

<sup>2</sup> Claim 26 (New) The compounds according to Claim 25, in which Ar<sup>1</sup>, Ar<sup>2</sup> and Ar<sup>3</sup> each independently stands for phenyl which is optionally substituted with halogen or lower alkyl; n is 1 or 2; s is 1; and R<sup>1</sup> is hydrogen.

<sup>3</sup> Claim 27 (New) The compounds according to Claim 26, which are represented by the general formula [I-a]:




wherein A<sup>1</sup> stands for a group represented by the formula [a<sub>1</sub>]




R<sup>2a</sup> and R<sup>3a</sup> each independently stands for hydrogen, or optionally substituted lower alkyl, the substituent being selected from hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl; R<sup>8</sup> stands for hydrogen, halogen or lower alkyl; and R<sup>60</sup> stands for hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl,

lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 28 (New) The compounds according to Claim 26, which are represented by the general formula [I-b]:




wherein A<sup>1a</sup> stands for a group of the formula [a<sub>1</sub>]




R<sup>8</sup> stands for hydrogen, halogen or lower alkyl; and R<sup>60</sup> stands for hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 29 (New) The compounds according to Claim 26, which are represented by the general formula [I-c]:




in which A<sup>1</sup> stands for a group represented by the formula [a<sub>1</sub>]




R<sup>8</sup> stands for hydrogen, halogen or lower alkyl; and R<sup>60</sup> stands for hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 30 (New) The compounds according to Claim 26, which are represented by the general formula [I-d]




in which A<sup>1a</sup> stands for a group of the formula [a<sub>1</sub>]





R<sup>8</sup> stands for hydrogen, halogen or lower alkyl; R<sup>60</sup> stands for hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

7  
2  
Claim 21 (New) The compounds according to Claim 26, which are represented by the general formula [I-e]



in which  $\text{A}^1$  stands for a group represented by the formula [a<sub>1</sub>]



$n_1$  stands for 1 or 2;  $\text{R}^{e1}$ ,  $\text{R}^{e2}$ ,  $\text{R}^{e3}$  and  $\text{R}^{e4}$  each independently stands for hydrogen, hydroxyl, amino, lower alkoxy, lower alkanoyloxy, lower alkylamino, di-lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, imidazolyl and a group represented by  $-\text{R}^7$ ; or  $\text{R}^{e1}$  and  $\text{R}^{e2}$  together signify oxo group;  $\text{R}^7$  stands for optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkoxycarbonyl and imidazolyl;  $\text{R}^8$  stands for hydrogen, halogen or lower alkyl; and  $\text{R}^{60}$  stands for hydrogen,  $\text{C}_1\text{-C}_{10}$  alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 32 (New) The compounds according to Claim 31, in which R<sup>e1</sup> is hydrogen or hydroxyl, and all of R<sup>e2</sup>, R<sup>e3</sup> and R<sup>e4</sup> are hydrogen.

Claim 33 (New) The compounds according to any one of claims 25 to 32, in which R<sup>60</sup> is hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl or cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl.

Claim 34 (New) The compounds according to Claim 33, in which said C<sub>1</sub>-C<sub>10</sub> alkyl as R<sup>60</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl, heptyl, octyl or decyl.

Claim 35 (New) The compounds according to Claim 33, in which said cycloalkyl group as R<sup>60</sup> is cyclopentyl or cyclohexyl.

Claim 36 (New) The compounds according to Claim 33, in which said cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl as R<sup>60</sup> is cyclopropylmethyl, cyclobutylmethyl, 2-(1-methylcyclopropyl)ethyl, cyclopentylmethyl, (2,2-dimethylcyclopentyl)methyl, 1-cyclopentylethyl, cyclohexylmethyl or 1-cyclohexylethyl.

Claim 37 (New) A pharmaceutical composition for the treatment of diseases associated with muscarinic M<sub>3</sub> receptors, which comprises a muscarinic M<sub>3</sub> antagonistically effective amount of compound of formula [I] according to Claim 25 or a salt thereof, and a pharmaceutically acceptable adjuvant.

Claim 38 (New) A method for the treatment of chronic obstructive pulmonary diseases, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema and rhinitis; irritable bowel syndrome, convulsive colitis, gastroduodenal ulcer, convulsion or hyperanakinesia of digestive tract, diverticulitis and pain accompanying contraction of smooth muscles of the digestive system; urinary incontinence, urgency and pollakiuria in nervous pollakiuria, neurogenic bladder, nocturnal enuresis, unstable bladder, cystospasm and chronic cystitis; and motion sickness, which comprises administering a muscarinic M<sub>3</sub> antagonistically effective amount of compound of formula [I] according to Claim 25 or a salt thereof to a patient suffering from the diseases.

**REMARKS**

Favorable reconsideration is respectfully requested.

The claims are 20 and 25-30.

The above amendment makes minor editorial corrections to claim 20 and presents a new set of claims wherein claim 25 is the new main claim.

Claims 26-36 ultimately depend on new claim 25. New claims 37 and 38 replace previous claims 23 and 24, respectively.

The above amendment is responsive to points set forth in the Official Action.

With regard to Official Action paragraph 1, the Official Action states that claims 3 and 15-22 are drawn to a non-elected invention and withdrawn. However, it is considered that claim 20 should be retained since it is within the scope of the elected invention i.e. Group I.

With regard to Official Action paragraph 2, claims 23 and 24 have been canceled and replaced by claims 37 and 38 respectively, which are free from the rejections under 35 U.S.C. 112, second paragraph.

No further issues remaining, allowance of this application is respectfully requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact undersigned at the telephone number below.

Respectfully submitted,

Yufu SAGARA et al.

By: Matthew Jacob  
Matthew Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/da  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 29, 2003

U.S. COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 25-0975.